Emactuzumab (RG7155) is a CSF-1R antibody that blocks CSF-1R dimerization in CSF-1R+CD163+ TAMs to deplete them from the tumor microenvironment, alone or in combination with other anti-cancer drugs [160,161]. This evidence concerns the gene CSF1R and cancer.